Sign In
Buy FREQ
$0.300
+0 (+0%)
At Close: Feb 02, 2024
Why Frequency Therapeutics Stock Is Crashing Today
12:12pm, Tuesday, 23'rd Mar 2021
The company announced disappointing results from a phase 2a study.
FREQ Stock Price Falls Over 70% Pre-Market: Why It Happened
08:47am, Tuesday, 23'rd Mar 2021
The stock price of Frequency Therapeutics Inc (NASDAQ: FREQ) fell by over 70% pre-market. This is why it happened.
Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock?
12:52pm, Monday, 22'nd Mar 2021
Frequency Therapeutics, Inc. (FREQ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Do Options Traders Know Something About Frequency Therapeutics (FREQ) Stock We Don't?
09:50am, Monday, 22'nd Mar 2021
Investors need to pay close attention to Frequency Therapeutics (FREQ) stock based on the movements in the options market lately.
Earnings Preview: Frequency Therapeutics, Inc. (FREQ) Q4 Earnings Expected to Decline
01:16pm, Thursday, 18'th Mar 2021
Frequency Therapeutics, Inc. (FREQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Frequency Therapeutics' FX-322 Data Published In Peer-Reviewed Journal
07:12am, Tuesday, 23'rd Feb 2021
Frequency Therapeutics Inc (NASDAQ: FREQ) has announced the publication of its lead candidate FX-322 Phase 1/2 study results in Otology & Neurotology. The data was initially announced in April 2019
Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning
07:00am, Monday, 08'th Feb 2021
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused b
Why Anthem, Frequency Therapeutics And Vir Are Moving Today
12:38pm, Wednesday, 27'th Jan 2021
Vir Biotechnology (NASDAQ: VIR) shares are trading lower Wednesday after JPMorgan downgraded the stock from Neutral to Underweight and announced a price target of $30 per share. Vir Biotechnology is a
Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer
07:30am, Tuesday, 19'th Jan 2021
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused b
Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference
07:30am, Tuesday, 05'th Jan 2021
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused b
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused b
Frequency Therapeutics (FREQ) in Focus: Stock Moves 5.3% Higher
09:47am, Thursday, 17'th Dec 2020
Frequency Therapeutics (FREQ) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer
07:30am, Tuesday, 01'st Dec 2020
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused b
Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial Results
07:30am, Monday, 16'th Nov 2020
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused b
Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
12:59pm, Monday, 09'th Nov 2020
Frequency Therapeutics is using novel progenitor cell stimulating technology to regrow hair cells in the ear and improve hearing loss in patients. Progenitor cells are found all throughout the body, s
